---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-006521"
form_type: "8-K"
ticker: "ZSQR"
cik: "0001759186"
company_name: "Z Squared Inc."
filed_at: "2024-09-19T23:59:59+00:00"
generated_at: "2026-05-31T03:40:54.317775+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Coeptis Therapeutics gets Nasdaq extension to Jan 15, 2025 to regain $1 bid price compliance

## Summary
- Nasdaq Hearings Panel granted continued listing through Jan 15, 2025, subject to compliance with Minimum Bid Price Requirement.
- Company plans to implement a reverse stock split to regain compliance.
- Original non-compliance notice received Jan 29, 2024; previous compliance period ended July 29, 2024.
- CEO Dave Mehalick expressed optimism about regaining and maintaining Nasdaq listing.
- Extension follows a hearing on Sep 12, 2024; company had appealed earlier delisting determination.

## SEC filing metadata
- accession: 0001683168-24-006521
- form_type: 8-K
- ticker: ZSQR
- cik: 0001759186
- company_name: Z Squared Inc.
- filed_at: 2024-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759186/000168316824006521/0001683168-24-006521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759186/000168316824006521/coeptis_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-006521
- JSON: https://secwatch.observer/filing/0001683168-24-006521.json
- Plain text: https://secwatch.observer/filing/0001683168-24-006521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.